Lupin Licenses LG's Insulin Glargine For India
This article was originally published in PharmAsia News
Executive Summary
Lupin and LG Life Sciences have agreed to a licensing agreement for the India-based company to market and distribute the South Korea drug maker's Basugine (glargine) insulin in India.